Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 7:12 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 141 - 160 ( 222 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SYRS Lining up Key Data updates in Upcoming Months through 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Takeaways from KOL Breakfast Discussing CDK7?s Potential in Ovarian and Breast Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cycling through 1365 and 5609 updates through 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Milestones in 2019; Maintain Buy - $14 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Refining Ovarian Strategy by Adding Clear Cell - Subtracting Primary Refractory
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Pivots Should De-Risk Clinical Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
California Dreamin? I: Biotech Stories To Keep An Eye On
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2018: Key Presentations Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1425 Update in Newly Diagnosed AML Shows Activity with Aza
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D